At present, topical eye drops remain the most common method for treating ocular disease, accounting for 90% of all ophthalmic formulations; however, ocular anatomy and physiology present several barriers that derail the effective and efficient delivery of medications from eye drops. For instance, to achieve antimicrobial efficacy, antibiotic eye drops require frequent instillation, exposing to the risk of patient non-adherence and consequent inefficacy of treatment regimens. Antibiotic-loaded insert formulations offer the opportunity to address challenges in ocular drug delivery, but none is currently available on the market.
Following the successful development and characterisation of an antibiotic-loaded ocular insert within our research group [1], capable of releasing antibiotic drug in a controlled manner above the minimum inhibitory concentration (MIC) of model gram +ve and gram -ve bacteria, the current project aims to sustain drug release from this platform and establish its application for treatment of other diseases of the anterior segment. The inserts will be tailored to accommodate a variety of drug classes, making them versatile for addressing a spectrum of ocular diseases, including glaucoma, macular degeneration, and inflammatory conditions. This work will utilise a quality by design (QbD) approach [2] to ensure quality, safety, and efficacy of formulated medicines in terms of physico-chemical characterisation, mechanical characterisation, and biological interactions utilising mammalian and bacterial cell culture. Concepts such as fixed dose combinations will also be explored, all to reduce the drug burden for patients and enhance compliance. Development of bioerodible inserts as a foundational framework for ocular drug delivery presents a revolutionary solution to improve the management of diverse ocular diseases. The controlled release features inherent in these inserts have the capacity to transform therapeutic results significantly, presenting a promising pathway for the advancement of inventive ocular drug delivery systems.
References:
Desiato, A.; Iyire, A.; Bhogal-Bhamra, P.; Naroo, S.; Gil-cazorla, R. (2022) Optimisation and evaluation of a soluble ocular insert for sustained release of levofloxacine. Ivestigative Ophthalmology & Vision Science 63(7): 3959–A0239-3059–A0239 Dahmash, E.Z.; Al-khattawi, A.; Iyire, A.; Al-Yami, H.; Denisson, T.; Mohammed, A.R. (2018) Quality by Design (QbD) based process optimisation to develop functionalised particles with modified release properties using novel dry particle coating technique. PloS One 13(11): e0206651